Mark F. Kubik

Corporate Officer/Principal bei GENOR BIOPHARMA HOLDINGS LIMITED

60 Jahre

Health Technology

Consumer Services

Profil

Mark F.
Kubik is currently the Chief Business Officer at Genor Biopharma Holdings Ltd.
He previously worked as the Head of Business Development at Merck & Co., Inc., and as the Chief Business Officer at Actinium Pharmaceuticals, Inc. and OncoImmune, Inc. Kubik received his undergraduate degree from the University of Colorado Boulder and his MBA from The Leeds School of Business.

Aktive Positionen von Mark F. Kubik

Unternehmen	Position	Beginn
GENOR BIOPHARMA HOLDINGS LIMITED	Corporate Officer/Principal	17.08.2021

Alle aktiven Positionen von Mark F. Kubik

Ehemalige bekannte Positionen von Mark F. Kubik

Unternehmen	Position	Ende
OncoImmune, Inc. OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD.	Corporate Officer/Principal	-
MERCK & CO., INC.	Corporate Officer/Principal	-
ACTINIUM PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

Sehen Sie sich die Erfahrung von Mark F. Kubik im Detail an

Ausbildung von Mark F. Kubik

The Leeds School of Business	Masters Business Admin
University of Colorado Boulder	Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Mark F. Kubik im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	3
ACTINIUM PHARMACEUTICALS, INC.	Health Technology
GENOR BIOPHARMA HOLDINGS LIMITED	Health Technology
MERCK & CO., INC.	Health Technology

Private Unternehmen	1
OncoImmune, Inc. OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD.	Health Technology